𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

✍ Scribed by Semra Aydin; Ulrich Dührsen; Holger Nückel

Publisher
Springer
Year
2007
Tongue
English
Weight
125 KB
Volume
86
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Equitoxicity of bolus and infusional eto
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)
✍ Carsten Zwick; Josef Birkmann; Norma Peter; Heinrich Bodenstein; Roland Fuchs; M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 259 KB
A controversial issue: could a watch-and
A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre study
✍ Svetislav Jelić; Olivera Frim; Gordana Gligorijević; Dušica Gavrilović; Nebojša 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 2 views

Background: A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied